Chemo-immunotherapy in RCC: the end of a story

The Lancet

Volumn 375, Issue 9715, 2010, Pages 613-614

  Escudier, Bernard ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BEVACIZUMAB; CYTOKINE; EVEROLIMUS; FLUOROURACIL; INTERFERON; INTERLEUKIN 2; NEW DRUG; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

EID: 76749147303     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60209-7     Document Type: Note

References (16)

1. Rosenberg S.A., Lotze M.T., Muul L.M., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313 (1985) 1485-1492
2. Medical Research Council Renal Cancer Collaborators. Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353 (1999) 14-17
3. Yang J.C., Topalian S.L., Parkinson D., et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 12 (1994) 1572-1576
4. West W.H., Tauer K.W., Yanelli J.R., et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316 (1987) 898-905
5. Negrier S., Escudier B., Lasset C., et al. Interleukin-2, interferon or both in 425 patients with metastatic renal cell cancer: results of a multicenter randomized trial. N Engl J Med 338 (1998) 1272-1278
6. Hänninen E.L., Kirchner H., and Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 155 (1996) 19-25
7. Atzpodien J., Kirchner H., Illiger H.J., et al. IL-2 in combination with IFN-α and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 85 (2001) 1130-1136
8. Atzopdien J., Kirchner H., Jonas U., et al. Interleukin-2 and interferon alfa-2a based immunotherapy in advanced renal cell carcinoma: prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22 (2004) 1188-1194
9. Negrier S., Caty A., Lesimple T., et al., for the Groupe Français d'Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. Treatment of patients with metastatic renal carcinioma with a combination of subcutaneous interleukin 2 and interferon alfa with or without fluorouracil. J Clin Oncol 18 (2000) 4009-4015
10. Gore M.E., Griffin C.L., Hancock B., et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 375 (2010) 641-648
11. Motzer R., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
12. Escudier B., Pluzanska A., Koralewski P., et al., for the AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
13. Escudier B., Szczylik C., Hutson T.E., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27 (2009) 1280-1289
14. Negrier S., Perol D., Ravaud A., et al. Medroxyprogesterone, interferon alpha-2a, interleukin 2 or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110 (2007) 2468-2477
15. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27 (2009) 3584-3590
16. Rini B.I., Halabi S., Rosenberg J.E., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26 (2008) 5422-5428